Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
Last trade$2.88
Day change-$0.15 (-4.95%)
Day range$2.87 – $3.07
Volume619,398
Market cap$255M
OpenXASE
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$255.49M
Price / earnings
12.43×
Price / book
3.17×
Price / sales
3.02×
EV / sales
2.76×
EV / EBITDA
8.7×
Profitability
Earnings per share
$0.24
Return on assets
17.38%
Return on equity
25.51%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
3.27×
Quick ratio
2.14×
Cash ratio
0.73×
Cash flow
Price / cash flow
14.55×
Price / free cash flow
16.96×
Free cash flow
$15.07M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PLX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$21.93M
$19.9M
$33.75M
$9.12M
$17.85M
$15.66M
$10.11M
$18.22M
Cost of revenue
$7.88M
$7.76M
$4.13M
$4.62M
$8.32M
$5.87M
$8.18M
$3.89M
Gross profit
$14.05M
$12.13M
$29.62M
$4.5M
$9.53M
$9.79M
$1.93M
$14.33M
Selling, general and administrative
$3.08M
$3.11M
$3.05M
$3.53M
$2.93M
$2.62M
$2.6M
$3M
Research and development
$6.92M
$4.35M
$5.43M
$5.64M
$4.47M
$5.99M
$3.48M
$4.12M
Total operating expenses
$10M
$7.46M
$8.48M
$9.16M
$7.4M
$8.62M
$6.08M
$7.12M
Operating income
$4.05M
$4.67M
$21.15M
-$4.66M
$2.13M
$1.17M
-$4.15M
$7.21M
Interest expense
-$24K
-$494K
-$193K
-$383K
-$180K
-$783K
-$6K
-$6K
Income before taxes
$4.62M
$4.86M
$21.14M
-$4.78M
$2.24M
$661K
-$3.73M
$7.32M
Income taxes
$661K
$1.08M
$2.82M
$728K
-$116K
$497K
-$113K
$822K
Net income
$3.96M
$3.78M
$18.32M
-$5.5M
$2.36M
$164K
-$3.62M
$6.49M
Net income attributable to common shareholders
$3.96M
$3.78M
$18.32M
-$5.5M
$2.36M
$164K
-$3.62M
$6.49M
EBITDA
$4.47M
$5.08M
$21.55M
-$4.27M
$2.5M
$1.53M
-$3.8M
$7.54M
Basic earnings per share
$0.05
$0.05
$0.23
-$0.07
$0.03
$0.00
-$0.05
$0.09
Diluted earnings per share
$0.05
$0.05
$0.22
-$0.07
$0.03
$0.00
-$0.05
$0.07
Recent news
Company coverage with links to the original publishers.
Protalix reported Q2 2026 revenues of $19.9 million, up from $15.7 million year-over-year, driven by Elfabrio sales through its Chiesi partnership. The company posted net income of $3.8 million ($0.05 per share) and H1 net income of $22.1 million. Full-year 2026 revenue guidance remains $78-83 million. The company maintains a strong cash position of $40.7 million with zero debt and expects PRX-115 Phase 2 RELEASE study top-line results in H2 2027.
The European Commission has approved a new every-4-weeks dosing regimen (2mg/kg) for Elfabrio® (pegunigalsidase alfa) in adults with Fabry disease who are stable on enzyme replacement therapy. This approval extends the infusion interval from every 2 weeks, reducing treatment burden for patients and healthcare systems. Protalix is entitled to a $25 million regulatory milestone payment from Chiesi. The FDA-approved dosing in the US remains unchanged at 1mg/kg every 2 weeks.
The global Fabry disease treatment market is expected to grow from $2.76 billion in 2024 to $7.02 billion by 2034, at a CAGR of 9.8%. Key factors driving the market include FDA clearance of Fabry disease drugs and increased R&D investment.